Population
Patients with metabolic syndrome and cardiovascular disease (general discussion)
Design
Review
Authors
Loading...
Requires rigorous trials before therapeutic use; leaves open Angptl2/6 as CVD targets from review evidence alone.
Angptl2 and Angptl6/AGF represent potential novel molecular targets for the prevention and treatment of metabolic syndrome and cardiovascular disease.
Oike et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: